221 related articles for article (PubMed ID: 27084653)
21. Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy.
Schwartz DL; Hutcheson K; Barringer D; Tucker SL; Kies M; Holsinger FC; Ang KK; Morrison WH; Rosenthal DI; Garden AS; Dong L; Lewin JS
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1356-65. PubMed ID: 20646872
[TBL] [Abstract][Full Text] [Related]
22. Intensity-modulated radiotherapy for oropharyngeal squamous cell carcinoma.
Mendenhall WM; Amdur RJ; Morris CG; Kirwan JM; Li JG
Laryngoscope; 2010 Nov; 120(11):2218-22. PubMed ID: 20938964
[TBL] [Abstract][Full Text] [Related]
23. Toxicity and outcome of intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy for oropharyngeal cancer: a matched-pair analysis.
Al-Mamgani A; Van Rooij P; Tans L; Teguh DN; Levendag PC
Technol Cancer Res Treat; 2013 Apr; 12(2):123-30. PubMed ID: 23098281
[TBL] [Abstract][Full Text] [Related]
24. A multi-institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity-modulated radiotherapy.
Setton J; Lee NY; Riaz N; Huang SH; Waldron J; O'Sullivan B; Zhang Z; Shi W; Rosenthal DI; Hutcheson KA; Garden AS
Cancer; 2015 Jan; 121(2):294-301. PubMed ID: 25286832
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Outcomes After Proton Beam Therapy for Sinonasal Squamous Cell Carcinoma.
Russo AL; Adams JA; Weyman EA; Busse PM; Goldberg SI; Varvares M; Deschler DD; Lin DT; Delaney TF; Chan AW
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):368-376. PubMed ID: 27084654
[TBL] [Abstract][Full Text] [Related]
26. A comparison of outcomes using intensity-modulated radiation therapy and 3-dimensional conformal radiation therapy in treatment of oropharyngeal cancer.
Lohia S; Rajapurkar M; Nguyen SA; Sharma AK; Gillespie MB; Day TA
JAMA Otolaryngol Head Neck Surg; 2014 Apr; 140(4):331-7. PubMed ID: 24557509
[TBL] [Abstract][Full Text] [Related]
27. Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes.
Gensheimer MF; Liao JJ; Garden AS; Laramore GE; Parvathaneni U
Radiat Oncol; 2014 Nov; 9():255. PubMed ID: 25424729
[TBL] [Abstract][Full Text] [Related]
28. Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy.
Taku N; Wang L; Garden AS; Rosenthal DI; Gunn GB; Morrison WH; Fuller CD; Phan J; Reddy JP; Moreno AC; Spiotto MT; Chronowski G; Shah SJ; Mayo LL; Gross ND; Ferrarotto R; Zhu XR; Zhang X; Frank SJ
Curr Treat Options Oncol; 2021 Jun; 22(6):54. PubMed ID: 34086150
[TBL] [Abstract][Full Text] [Related]
29. Adaptive radiotherapy for head-and-neck cancer: initial clinical outcomes from a prospective trial.
Schwartz DL; Garden AS; Thomas J; Chen Y; Zhang Y; Lewin J; Chambers MS; Dong L
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):986-93. PubMed ID: 22138459
[TBL] [Abstract][Full Text] [Related]
30. High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial.
Lertbutsayanukul C; Kitpanit S; Kannarunimit D; Chakkabat C; Oonsiri S; Thephamongkhol K; Puataweepong P; Katanyoo K; Sukhaboon J; Tovanabut C; Chongsathientham S; Treeratsapanich P; Soonthornrak J; Prayongrat A
Trials; 2022 Oct; 23(1):897. PubMed ID: 36273186
[TBL] [Abstract][Full Text] [Related]
31. Spot scanning proton arc therapy reduces toxicity in oropharyngeal cancer patients.
de Jong BA; Battinelli C; Free J; Wagenaar D; Engwall E; Janssens G; Langendijk JA; Korevaar EW; Both S
Med Phys; 2023 Mar; 50(3):1305-1317. PubMed ID: 36373893
[TBL] [Abstract][Full Text] [Related]
32. Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma.
Goepfert RP; Lewin JS; Barrow MP; Fuller CD; Lai SY; Song J; Hobbs BP; Gunn GB; Beadle BM; Rosenthal DI; Garden AS; Kies MS; Papadimitrakopoulou VA; Schwartz DL; Hutcheson KA
Laryngoscope; 2017 Apr; 127(4):842-848. PubMed ID: 27440393
[TBL] [Abstract][Full Text] [Related]
33. A Model-Based Approach to Predict Short-Term Toxicity Benefits With Proton Therapy for Oropharyngeal Cancer.
Rwigema JM; Langendijk JA; Paul van der Laan H; Lukens JN; Swisher-McClure SD; Lin A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):553-562. PubMed ID: 30625409
[TBL] [Abstract][Full Text] [Related]
34. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.
Leeman JE; Li JG; Pei X; Venigalla P; Zumsteg ZS; Katsoulakis E; Lupovitch E; McBride SM; Tsai CJ; Boyle JO; Roman BR; Morris LGT; Dunn LA; Sherman EJ; Lee NY; Riaz N
JAMA Oncol; 2017 Nov; 3(11):1487-1494. PubMed ID: 28542679
[TBL] [Abstract][Full Text] [Related]
35. Proton therapy and oral mucositis in oral & oropharyngeal cancers: outcomes, dosimetric and NTCP benefit.
Nangia S; Gaikwad U; Noufal MP; Sawant M; Wakde M; Mathew A; Chilukuri S; Sharma D; Jalali R
Radiat Oncol; 2023 Jul; 18(1):121. PubMed ID: 37468950
[TBL] [Abstract][Full Text] [Related]
36. The impact of treatment modality and radiation technique on outcomes and toxicity of patients with locally advanced oropharyngeal cancer.
Al-Mamgani A; van Rooij P; Verduijn GM; Mehilal R; Kerrebijn JD; Levendag PC
Laryngoscope; 2013 Feb; 123(2):386-93. PubMed ID: 23404489
[TBL] [Abstract][Full Text] [Related]
37. Impact of Expression of CD44, a Cancer Stem Cell Marker, on the Treatment Outcomes of Intensity Modulated Radiation Therapy in Patients With Oropharyngeal Squamous Cell Carcinoma.
Motegi A; Fujii S; Zenda S; Arahira S; Tahara M; Hayashi R; Akimoto T
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):461-8. PubMed ID: 26867875
[TBL] [Abstract][Full Text] [Related]
38. Clinical results of definitive intensity-modulated radiation therapy for oropharyngeal cancer: retrospective analysis of treatment efficacy and safety.
Kimura K; Kodaira T; Tomita N; Tachibana H; Makita C; Yoshida M; Nishikawa D; Hirakawa H; Suzuki H; Hanai N; Hasegawa Y
Jpn J Clin Oncol; 2016 Jan; 46(1):78-85. PubMed ID: 26496935
[TBL] [Abstract][Full Text] [Related]
39. Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
Chera BS; Amdur RJ; Tepper J; Qaqish B; Green R; Aumer SL; Hayes N; Weiss J; Grilley-Olson J; Zanation A; Hackman T; Funkhouser W; Sheets N; Weissler M; Mendenhall W
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):976-85. PubMed ID: 26581135
[TBL] [Abstract][Full Text] [Related]
40. Radiotherapy dose-volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: Results of a prospective registry.
Kamal M; Mohamed ASR; Volpe S; Zaveri J; Barrow MP; Gunn GB; Lai SY; Ferrarotto R; Lewin JS; Rosenthal DI; Jethanandani A; Meheissen MAM; Mulder SL; Cardenas CE; Fuller CD; Hutcheson KA;
Radiother Oncol; 2018 Sep; 128(3):442-451. PubMed ID: 29961581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
